Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
13 hedge funds and large institutions have $5.66M invested in Yield10 Bioscience, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 9 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
32% less funds holding
Funds holding: 19 → 13 (-6)
38% less capital invested
Capital invested by funds: $9.12M → $5.66M (-$3.46M)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
+$132K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$43.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.2K |
| 5 |
BlackRock
New York
|
+$6.89K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$231K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$202K |
| 3 |
Morgan Stanley
New York
|
-$202K |
| 4 |
Two Sigma Advisers
New York
|
-$198K |
| 5 |
Renaissance Technologies
New York
|
-$196K |
YTEN Hedge Fund Activity: Q3 2021 in Review
13 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q3 2021, worth a combined $5.66M — down 38% from $9.12M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of YTEN and 3 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Birchview Capital, opening a new position worth an estimated $132K. The largest seller was Marshall Wace North America, exiting entirely with an estimated $231K sold.
- 13 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q3 2021, down from 19 in Q2 2021.
- Funds reported $5.66M of Yield10 Bioscience, Inc. Common Stock stock for Q3 2021, down 38% quarter-over-quarter.
- 3 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q3 2021 and 9 closed out, a net change of -6 holders.
- The largest Yield10 Bioscience, Inc. Common Stock buyer in Q3 2021 was Birchview Capital, an estimated $132K added.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q3 2021 was Marshall Wace North America, an estimated $231K sold.
Based on aggregated 13F filings for Q3 2021.